NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01876953 2022-03-31Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid LeukemiaCity of Hope Medical CenterPhase 1/2 Terminated20 enrolled 9 charts
NCT01620216 2021-11-04Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaOHSU Knight Cancer InstitutePhase 2 Terminated12 enrolled 12 charts
NCT01643603 2020-12-17Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic MalignanciesBarbara Ann Karmanos Cancer InstitutePhase 1 Terminated5 enrolled